Mermaid Medical Group® is excited to announce that our partner, Danderyd Hospital in Sweden, is now offering microwave ablation (MWA) as a treatment for uterine fibroids, following the success of several clinical studies.
As of February 2025, Mermaid Medical is offering CPD-accredited workshops focused on Local Anaesthetic Transperineal Prostate (LATP) biopsy procedures.
Following the recent UKCA approval of TP Pivot Pro™, Prof. Hashim U. Ahmed has successfully performed the first European cases of transperineal prostate biopsies with the disposable needle guide designed by CIVCO Medical Solutions.
Mermaid Medical Group® Announces Exclusive Distribution Agreement for COBRA-OS® Device in the UK for REBOA Procedures with Front Line Medical Technologies Inc.
With its recent UKCA approval, Mermaid Medical is ready to introduce the TP Pivot Pro™ to UK healthcare professionals.
2024 marks a significant milestone in our journey toward sustainability - we achieved ISO 14001 certification, underscoring our commitment to reducing our environmental footprint.
Mermaid Medical Group announces new exclusive distribution deal on the COBRA-OS® device for REBOA procedures from Front Line Medical Technologies Inc.
Mermaid Medical is proud to announce the appointment of Marcus Kildegaard Nielsen as the new global Sales Director, effective September 1st, 2024. Over the past six years, Marcus has made significant contributions in sales and marketing, bringing the right skills, ambitions, and mindset to ensure we keep driving the business forward.
Mermaid Medical proudly welcomes Daniel Nilsson Lennartz as the new Business Development Director, effective September 1st, 2024. As one of the co-founders, Daniel brings invaluable insights and expertise that will continue to drive the company’s growth and long-term success.